Evidence map›Paper›PMID 39457680›Full record

ArticleBiomedicines2024

Systemic Innate Immune System Restoration as a Therapeutic Approach for Neurodegenerative Disease: Effects of NP001 on Amyotrophic Lateral Sclerosis (ALS) Progression.

Michael S McGrath, Rongzhen Zhang, Paige M Bracci, Ari Azhir, Bruce D Forrest

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michael S McGrathDepartment of Medicine, University of California San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0002-7232-2602
Rongzhen ZhangDepartment of Medicine, University of California San Francisco, San Francisco, CA 94110, USA.
Paige M BracciDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-9338-9307
Ari AzhirNeuvivo, Inc., Palo Alto, CA 94301, USA.
Bruce D ForrestNeuvivo, Inc., Palo Alto, CA 94301, USA.ORCID 0009-0003-3348-8604

Funding

Neuvivo, Inc. Neuvivo-NP001
6 · The paper itself

Abstract

BACKGROUND/

objectiveAmyotrophic lateral sclerosis (ALS) is a diagnosis that incorporates a heterogeneous set of neurodegenerative processes into a single progressive and uniformly fatal disease making the development of a uniformly applicable therapeutic difficult. Recent multinational ALS natural history incidence studies have identified systemic chronic activation of the innate immune system as a major risk factor for developing ALS. Persistent immune activation in patients with ALS leads to loss of muscle and lowering of serum creatinine. The goal of the current study was to test whether the slowing of nerve and muscle destruction in NP001-treated ALS patients compared with controls in phase 2 studies would lead to extension of survival.

methodsPhase 2 clinical studies with NP001, an intravenously administered form of the innate immune system regulator NaClO

conclusionsThe observed longer survival in ALS patients with the greatest inflammation-associated muscle loss provides further evidence that ALS is a disease of ongoing innate immune dysfunction and that NP001 is a disease-modifying drug with sustained clinical activity.

Indexed as

ALScreatinineinnate immune activationmacrophageNP001survivalvital capacity

Identifiers

PMID39457680
PMCPMC11505581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.